Q4 2024 Biodesix Inc Earnings Call Transcript
Key Points
- Biodesix Inc (BDSX) reported a 45% year-over-year revenue growth, reaching $71.3 million in 2024.
- The company achieved a strong gross margin of 78% for the year, indicating efficient cost management.
- Lung diagnostic testing revenues grew by 43% over 2023, driven by a 40% increase in test volume and expanded reimbursement coverage.
- Biodesix Inc (BDSX) successfully conducted a pilot program to expand its sales force, demonstrating the viability of targeting primary care providers.
- The company expects to achieve adjusted EBITDA profitability in the second half of 2025, based on revenue growth and cost discipline.
- Despite improvements, Biodesix Inc (BDSX) reported a net loss of $42.9 million for 2024, though this was an 18% improvement over 2023.
- Operating expenses increased by 17% year-over-year, driven by higher sales and marketing costs and non-cash depreciation expenses.
- The company ended the year with $26.2 million in unrestricted cash, down from $31.4 million at the end of the third quarter.
- Biodesix Inc (BDSX) has not provided specific guidance on cash burn for 2025, creating uncertainty about future cash flow management.
- The company does not plan to launch or commercialize any new tests in 2025, potentially limiting short-term growth opportunities.
Good day and thank you for standing by. Welcome to the biodesis.
Q4 2024 earnings conference calls. (Operator Instructions) Please be advised that today's conference is being recorded. I would not like to turn the conference over to Chris Brinzey, bioethics, investor relations. Please go ahead.
Thank you, operator, and good afternoon everyone. Today, Bioodesics released results from the 4th quarter and full year of 2024.
Leading the call today will be Scott Hutton, Chief Executive Officer.
He is joined by Robin Harper Cowie, Chief Financial Officer. An audio recording of today's call and the press release announcement with the quarterly results can be found in the investor relations section of the company's website at biodesics.com.
As today's call includes forward-looking statements, we encourage you to review the statements contained in today's press release and the risks and uncertainties described in our SEC filings, which identify certain factors that may cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
